Enrique Grande

12.9k total citations · 3 hit papers
286 papers, 4.6k citations indexed

About

Enrique Grande is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Enrique Grande has authored 286 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Oncology, 97 papers in Epidemiology and 90 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Enrique Grande's work include Neuroendocrine Tumor Research Advances (86 papers), Lung Cancer Research Studies (71 papers) and Neuroblastoma Research and Treatments (60 papers). Enrique Grande is often cited by papers focused on Neuroendocrine Tumor Research Advances (86 papers), Lung Cancer Research Studies (71 papers) and Neuroblastoma Research and Treatments (60 papers). Enrique Grande collaborates with scholars based in Spain, United States and Italy. Enrique Grande's co-authors include Teresa Alonso‐Gordoa, Javier Molina‐Cerrillo, Jaume Capdevila, Juan J. Díez, Paula Jiménez‐Fonseca, Rocio García‐Carbonero, Alfredo Carrato, Jaume Capdevila, Pablo Gajate and Juan W. Valle and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Enrique Grande

268 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

2023 117 citations Matteo Santoni, Alessandro Rizzo et al. profile →
European Neuroendocrine Tumour Society ( ENETS ) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours

2023 96 citations Beata Kos‐Kudła, Enrique Grande et al. Journal of Neuroendocrinology profile →
European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for digestive neuroendocrine carcinoma

2023 75 citations Enrique Grande, Marianne Pavel et al. Journal of Neuroendocrinology profile →

Peers

Countries citing papers authored by Enrique Grande

Since Specialization

Citations

This map shows the geographic impact of Enrique Grande's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrique Grande with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrique Grande more than expected).

Fields of papers citing papers by Enrique Grande

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enrique Grande. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrique Grande. The network helps show where Enrique Grande may publish in the future.

Co-authorship network of co-authors of Enrique Grande

This figure shows the co-authorship network connecting the top 25 collaborators of Enrique Grande. A scholar is included among the top collaborators of Enrique Grande based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrique Grande. Enrique Grande is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC 2025 ·Oncology and Therapy ·Bernadett Szabados, Félix Guerrero‐Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, (unknown), Syed A. Hussain, Girish S. Kulkarni, Anne Wilson, Neal D. Shore, Srikala S. Sridhar, (unknown), (unknown), (unknown), (unknown), Rosemary E. Teresi, Tilman Todenhöfer	0
2	Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) 2025 ·DIGITAL.CSIC (Spanish National Research Council (CSIC)) ·(unknown), Jorge Hernando, Javier Molina‐Cerrillo, (unknown), Rocio García‐Carbonero, Àlex Teulé, Ana Custodio, Paula Jiménez‐Fonseca, Carlos López, Cinta Hierro, Alberto Carmona‐Bayonas, Vicente Alonso Orduña, Marta Llanos, Isabel Sevilla, (unknown), Teresa Alonso‐Gordoa, Inmaculada Gallego, (unknown), (unknown), Enrique Grande	0
3	Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) 2025 ·Clinical Cancer Research ·(unknown), Jorge Hernando, Javier Molina‐Cerrillo, (unknown), Rocio García‐Carbonero, Àlex Teulé, Ana Custodio, Paula Jiménez‐Fonseca, Carlos López, Cinta Hierro, Alberto Carmona‐Bayonas, Vicente Alonso Orduña, Marta Llanos, Isabel Sevilla, (unknown), Teresa Alonso‐Gordoa, Inmaculada Gallego, (unknown), (unknown), Enrique Grande	0
4	The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity 2025 ·Cell Reports ·(unknown), (unknown), (unknown), Eva Musulén, Rossana Lazcano, Chia-Kuei Mo, Verónica Dávalos, (unknown), Adrià Bernat‐Peguera, Margarita Romeo, Collin Tokheim, Jordi Barretina, Alexander J. Lazar, Li Ding, Enrique Grande, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	9
5	Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). 2024 ·Journal of Clinical Oncology ·Matt D. Galsky, Enrique Grande, Andrea Necchi, Alexandra Drakaki, Yohann Loriot, Sonia Franco, (unknown), Wei Zhang, Thomas Powles	0
6	Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice 2023 ·ESMO Open ·Petros Grivas, Enrique Grande, Ian D. Davis, (unknown), Marc‐Oliver Grimm, Shilpa Gupta, Philippe Barthélémy, (unknown), Silke Guenther, (unknown), Cora N. Sternberg	12
7	Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 2023 ·Cancers ·Matteo Santoni, Javier Molina‐Cerrillo, Giorgio Santoni, Elaine T. Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo L. Rapoport, Enrique Grande, Sebastiano Buti	8
8	Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study 2023 ·Clinical Genitourinary Cancer ·Fernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, Zin Myint, Jindřich Kopecký, Jakub Kucharz, Thomas Büttner, Enrique Grande, María T. Bourlon, Javier Molina‐Cerrillo, Renate Pichler, Tomáš Büchler, Emmanuel Seront, (unknown), Aristotelis Bamias, (unknown), Nuno Vau, Camillo Porta, André P. Fay, Matteo Santoni	4
9	Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors 2022 ·Neuroendocrinology ·Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, (unknown), Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar	22
10	Single-Nucleotide Polymorphism Associations with Efficacy and Toxicity in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel 2022 ·Pharmacogenomics ·(unknown), Carmen Garrigós, (unknown), Javier Puente, (unknown), B. Mellado González, (unknown), Enrique Grande, Raquel Luque, Juan Antonio Virizuela Echaburu, (unknown), (unknown), Cristina Rodríguez‐Antona, Ignacio Durán	1
11	Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 2022 ·Cancers ·Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, (unknown), Matteo Rosellini, Elisa Tassinari, Javier Molina‐Cerrillo, Zin Myint, Tomáš Büchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari	10
12	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours 2021 ·Journal of Neuroendocrinology ·Clarisse Dromain, Marie‐Pierre Vullierme, Rodney J. Hicks, Vikas Prasad, (unknown), Wouter W. de Herder, Marianne Pavel, Antongiulio Faggiano, Beata Kos‐Kudła, Kjell Öberg, Guenter J. Krejs, Enrique Grande, Bruno Niederle, Anders Sundin	13
13	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 2020 ·Clinical Genitourinary Cancer ·Matteo Santoni, Francesco Piva, Camillo Porta, Sergio Bracarda, Daniel Y.C. Heng, Marc Matrana, Enrique Grande, Veronica Mollica, Gaetano Aurilio, Mimma Rizzo, Matteo Giulietti, Rodolfo Montironi, Francesco Massari	20
14	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 2020 ·European Urology ·Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert D. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh Huseni, Susheela Carroll, Roxana I. Sufan, Christina Schiff, Michael B. Atkins	60
15	Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs : Analysis of the Completed TELESTAR Extension Period 2018 ·Pancreas ·Martin O. Weickert, Gregory Kaltsas, Dieter Hörsch, Pablo Lapuerta, Marianne Pavel, Juan W. Valle, Martyn Caplin, Emily K. Bergsland, Pamela L. Kunz, Lowell Anthony, Enrique Grande, Kjell Öberg, Staffan Welin, Richard R.P. Warner, Catherine Lombard‐Bohas, (unknown), (unknown), (unknown), Qi Yang, Matthew H. Kulke	2
16	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours 2018 ·Cancer Treatment Reviews ·Jorge Barriuso, Ana Custodio, (unknown), Vicente Alonso, Aurora Astudillo, Jaume Capdevila, Rocio García‐Carbonero, Enrique Grande, Paula Jiménez‐Fonseca, Mónica Marazuela, Cristina Rodríguez‐Antona, Javier Aller	13
17	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe 2017 ·European Urology ·Johann S. de Bono, Simon Chowdhury, Susan Feyerabend, Tony Elliott, Enrique Grande, Amal Melhem‐Bertrandt, Benoît Baron, Mohammad Hirmand, Patrick Werbrouck, Karim Fizazi	80
18	Uso de fármacos para la osteoporosis en pacientes con diabetes mellitus tipo 2: estudio de cohortes de base poblacional 2017 ·SHILAP Revista de lepidopterología ·Daniel Martínez-Laguna, Carlen Reyes, Cristina Carbonell-Abella, Enrique Grande, (unknown), Dı́dac Mauricio, Adolfo Díez‐Pérez, Xavier Nogués, Daniel Prieto‐Alhambra	1
19	Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial 2016 ·Pancreas ·Matthew H. Kulke, Dieter Hoersch, Martyn Caplin, Lowell Anthony, Emily K. Bergsland, Kjell Öberg, Staffan Welin, Richard R.P. Warner, Catherine Lombard‐Bohas, Pamela L. Kunz, Enrique Grande, Juan W. Valle, Douglas Fleming, Pablo Lapuerta, Phillip Banks, Shanna Jackson, (unknown), Brian Zambrowicz, Arthur Sands, Marianne Pavel	1
20	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma 2013 ·SHILAP Revista de lepidopterología ·Enrique Grande, Jaume Capdevila, Juan J. Díez, Federico Longo, Alfredo Carrato	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact